Sangamo Therapeutics Inc (SGMO)
OTCHealth CareBiotechnologySnapshot 2026-11-04
$0.07+4.22%
Close 2026-07-28 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SGMO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -79.2% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
SGMO — legal / regulatory event — Bankruptcy or Receivership
Dated 2026-08-28
Bankruptcy or Receivership. As previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (the “Chapter 11 Case”). The case number is 26-10989 and the Chapter 11 Case is styled as In re Sangamo Therapeutics , I…
Why it matters: FDA acceptance would mark progress toward review of Sangamo's Fabry gene therapy. A rejection or stalled filing would weaken that path.
Watch forAn FDA notice accepts the completed ST-920 BLA for review and gives a review timeline.
Also watch forThe FDA rejects the BLA, asks Sangamo to stop the filing, or the company reports it cannot complete the BLA.
Why it matters: Court rulings can change what Sangamo can do during Chapter 11. The supplied event notices give no details on the claims or requested relief.
Watch forA court order lets Sangamo keep working and follow a plan to protect its named programs.
Also watch forA court order stops operations or asset use, or orders the company or key programs to close.
Why it matters: A court-approved plan could show whether Sangamo can keep the Fabry program alive. A sale or shutdown could stop that work.
Watch forA court filing or company update shows an approved plan and funding to continue ST-920 work and finish the BLA.
Also watch forA court filing or company update says ST-920 work will stop, or no funding remains to continue it.
Why it matters: The agreement may show who controls Sangamo's assets and programs during bankruptcy. Its terms can clarify whether key work can continue.
Watch forA filed agreement names a funder or partner. It provides funds to keep ST-920 or another named program active.
Also watch forThe filed agreement gives no funds for program work, or a later filing says key programs or assets will be shut down.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$0 on $10,000 · ±0.0% | How much price usually moves either way. |
| Bad day | Not available | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,017 loss on $10,000 · 70.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.